PLRX Pliant Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why PLRX matters now
Pliant Therapeutics, Inc. (PLRX) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.12 with -0.88% on the session and $69.4M in market capitalization; recent performance reads 1-month +0.87% and YTD -4.92%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-20.0M, and EPS of $-0.32. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -137.6%.
The latest indexable market news headline is "Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Hold with a median target of $3.00; recent insider activity includes Cline Darren S filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.43
P/S
0.00
EV/EBITDA
-0.73
DCF Value
$0.27
FCF Yield
-137.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-59.1%
ROA
-55.9%
ROIC
-61.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-20.0M | $-0.32 |
| Q4 2025 | $0.00 | $-23.6M | $-0.38 |
| FY 2025 | $0.00 | $-149.3M | $-2.43 |
| Q3 2025 | $0.00 | $-26.3M | $-0.43 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$3.00
Target (Median)
$3.00
Target Range
$3.00 - $3.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.21
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.